Total Funding
65
38
Total FundingConvertible Note raised
Growth Score
-3 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
73508
Umecrine Cognition is a developer of pharmaceutical products to treat cognitive neurological disorders.
- Torbjorn Backstrom: Co-Founder and CEO
Umecrine
About the Company
Umecrine Cognition is a developer of pharmaceutical products to treat cognitive neurological disorders caused by endogenous CNS-active steroids (GABA steroids). Its primary focus is on addressing the neurocognitive signs and symptoms associated with hepatic encephalopathy. By targeting the underlying biochemical mechanisms, the company aims to
enable healthcare providers to offer more precise and effective therapies for patients affected by this serious liver-related neurological condition.
